证券代码：600062 证券简称：华润双鹤 公告编号：临 2025－111 华润双鹤药业股份有限公司 关于董事离任的公告 华润双鹤药业股份有限公司(以下简称"公司")董事会近日收到 林国龙先生提交的书面辞职报告，其因工作安排原因，申请辞去第十 届董事会董事、审计与风险管理委员会委员职务。 董 事 会 一、提前离任的基本情况 2025 年 12 月 26 日 | | 离任职务 | 离任时间 | | | 原定任期 | | 离任 | 是否继续在上 市公司及其控 | 是否存在未 履行完毕的 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 姓名 | | | | | 到期日 | | 原因 | | | | | | | | | | | | 股子公司任职 | 公开承诺 | | 林国龙 | 董事、审计 与风险管理 | 2025 12 | 年 | 2027 | 年 | 7 | 工作安排 | 否 | 否 | | | 委员会委员 | 月 日 25 | | | 月 10 | 日 | | | | 二、离任对公司的影响 根据公司《章程》等相关规定，林国龙先生 ...

法律意见书 北京市中伦律师事务所 关于华润双鹤药业股份有限公司 2025 年第三次临时股东会的 法律意见书 致：华润双鹤药业股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公司 股东会规则》（以下简称"《股东会规则》"）、《律师事务所从事证券法律业 务管理办法》等法律、法规和规范性文件以及《华润双鹤药业股份有限公司章程》 （以下简称"《公司章程》"）的规定，北京市中伦律师事务所（以下简称"本 所"）作为华润双鹤药业股份有限公司（以下简称"公司"）的常年法律顾问， 指派律师出席公司 2025 年第三次临时股东会（以下简称"本次股东会"），并 依法出具本法律意见书。 本法律意见书仅就本次股东会的召集和召开程序是否符合法律、行政法规 及《公司章程》的规定，以及出席本次股东会人员的资格、召集人资格、会议表 决程序及表决结果是否合法有效发表意见，而不对本次股东会所审议的议案内 容以及该等议案所表述的相关事实或数据的真实性、准确性或合法性发表意 见。本次股东会通过网络投票系统进行投票的股东资格由网络投票系统提供机 构验证其身份。 为出具本法律意见书，本所律师列席了本次股东会，并根据有关法律、法 ...

2025 年第三次临时股东会 2025 年 12 月 25 日 证券代码：600062 证券简称：华润双鹤 公告编号：临 2025-109 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一) 股东会召开的时间：2025 年 12 月 25 日 (二) 股东会召开的地点：北京市朝阳区锐创国际中心 A 座 9 层 会议室 华润双鹤药业股份有限公司 2025年第三次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 (三) 出席会议的普通股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 449 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数(股) | 639,172,867 | | 3、出席会议的股东所持有表决权股份数占公司有 | 61.5324 | | 表决权股份总数的比例(%) | | (四) 表决方式是否符合《公司法》及公司《章程》的规定，股东 会主持情况等。 1、会议采取现场及网络方式投票表决，表决程序符合《公司法》 和公司《章程》的规 ...

每经头条（nbdtoutiao）——对话马斯克脑机接口"一号受试者"：大脑植入芯片23个月，我正重新夺回 人生的独立 （记者 王晓波） 每经AI快讯，华润双鹤（SH 600062，收盘价：18.48元）12月25日晚间发布公告称，华润双鹤药业股份 有限公司董事会近日收到林国龙先生提交的书面辞职报告，其因工作安排原因，申请辞去第十届董事会 董事、审计与风险管理委员会委员职务。 2025年1至6月份，华润双鹤的营业收入构成为：非输液占比75.13%，输液占比25.98%，分部间抵销占 比-1.11%。 截至发稿，华润双鹤市值为192亿元。 ...

南财智讯12月25日电，华润双鹤公告，公司董事会近日收到林国龙先生提交的书面辞职报告，其因工作 安排原因，申请辞去第十届董事会董事、审计与风险管理委员会委员职务。根据公司《章程》等相关规 定，林国龙先生的离任未导致公司董事会低于法定最低人数，上述辞职申请自送达董事会之日起生效。 截至本公告日，林国龙先生未持有本公司股票，不存在应当履行而未履行的承诺事项。 ...

Core Viewpoint - China Resources Double Crane Pharmaceutical Co., Ltd. announced that its wholly-owned subsidiary, Beijing Double Crane Run Chuang Technology Co., Ltd., received the clinical trial approval notice for the drug DC6001, which is intended for the treatment of Stargardt disease in adolescents [1][3]. Group 1: Drug Approval and Development - The drug DC6001 is aimed at treating Stargardt disease, a hereditary macular degeneration condition in adolescents [1]. - The clinical trial application for DC6001 was submitted to the National Medical Products Administration (NMPA) on October 9, 2025, and the approval notice was received on December 19, 2025 [1]. Group 2: Financial Investment - The total research and development investment for the drug DC6001 has reached approximately RMB 14.897 million (unaudited) as of the date of the announcement [2]. Group 3: Future Steps and Obligations - The company will actively promote the research and development project in accordance with national regulations and will fulfill its information disclosure obligations regarding subsequent progress [4].

Core Viewpoint - China Resources Double Crane Pharmaceutical Co., Ltd. announced that its wholly-owned subsidiary, Beijing Double Crane Run Chuang Technology Co., Ltd., has received the Drug Clinical Trial Approval Notice for DC6001 tablets from the National Medical Products Administration [2] Group 1 - The approval signifies a significant step in the development of DC6001 tablets, indicating progress in the company's research and development efforts [2] - The announcement reflects the company's commitment to advancing its pharmaceutical portfolio and enhancing its market position [2]

Group 1 - Shareholder of Okoyi plans to reduce holdings by up to 1.89% of the company's shares, amounting to a maximum of 3 million shares due to personal funding needs [1] - Tianchuang Fashion is planning a change in control, leading to continued suspension of its stock trading, expected to last no more than 3 trading days [2] - China Electric Power Construction Company reported a new contract amount of 10,317.55 billion yuan for the first 11 months of 2025, a year-on-year decrease of 1.65% [3] Group 2 - Pilin Bio's wholly-owned subsidiary received approval for a clinical trial of a drug, indicating progress in its product development [4] - Yihong Medical obtained two medical device registration certificates for diagnostic kits, enhancing its product portfolio [5] - Aohong Electronics plans to use up to 450 million yuan of idle fundraising for cash management, targeting safe and liquid financial products [6] Group 3 - China Electric Power Construction signed a contract worth approximately 6.626 billion yuan for a natural gas booster station project in Turkey, with a construction period of about 55 months [7] - Baosheng Co. won a bid for a power cable project in Singapore, valued at around 1.2 billion yuan, marking the largest overseas order in its history [8] - *ST Xinyan's stock will resume trading on December 24, 2025, following a capital increase plan that will raise its total share capital to 3.29 billion shares [9] Group 4 - Ningbo Construction's subsidiary signed a construction contract worth 428 million yuan for an engineering project with a duration of 990 days [11] - Lianhuan Pharmaceutical's subsidiary received approval for a drug that passed the consistency evaluation for generic drugs, enhancing its market competitiveness [12] - Zhongjie Automotive received a project designation for a new electric air conditioning compressor, with expected sales of approximately 29.86 million USD over its lifecycle [13] Group 5 - Biopharmaceuticals' major shareholder plans to increase holdings by 50 million to 100 million yuan, indicating confidence in the company's future [14] - Haizheng Pharmaceutical's subsidiary received approval for a veterinary drug product, expanding its product offerings in the animal health sector [15] - *ST Songfa's subsidiary signed contracts for the construction of 8 vessels, with a total contract value between 200 million to 400 million USD [16] Group 6 - Shandong Pharmaceutical Glass announced the resignation of its chairman due to age reasons, indicating a potential leadership transition [17] - Xinno Wei's subsidiary received approval for a clinical trial of a monoclonal antibody drug, indicating advancements in its drug development pipeline [18] - Ningbo Huaxiang's subsidiary secured an order for robot joints, expected to positively impact future business performance [19][20] Group 7 - China Resources Double Crane's subsidiary received approval for a clinical trial of a drug aimed at treating a genetic eye disease, reflecting ongoing R&D efforts [21] - Huaxin Technology's shareholders set a transfer price of 56.69 yuan per share for a block of shares, indicating active shareholder engagement [22] - Xinhua Net announced the resignation of its president due to job relocation, suggesting potential changes in management [23] Group 8 - Taiji Group plans to transfer a 40% stake in a subsidiary to focus on its core pharmaceutical business, enhancing operational efficiency [24] - Huaxin Construction's shareholder plans to increase holdings by 200 million to 400 million yuan, reflecting confidence in the company's prospects [25] - Dongjie Intelligent is planning to issue shares and cash for asset acquisition, with stock trading suspended until further notice [26] Group 9 - Wanrun New Energy was designated as a delivery warehouse for lithium carbonate futures, indicating its strategic position in the market [27] - Prolo Pharmaceutical's subsidiary received a drug registration certificate for an influenza treatment, expanding its product range [28] - Saiwu Technology invested 5 million yuan in a private equity fund focused on smart vehicles and energy innovation, indicating strategic investment in growth sectors [29] Group 10 - Bohui Innovation's subsidiary received approval for a clinical trial of an immunoglobulin drug, indicating progress in its product development [30] - Bohui Innovation's subsidiary also received a drug registration certificate for a coagulation factor product, enhancing its therapeutic offerings [31] - Hanghua Co. plans to allocate 146 million yuan of surplus fundraising for a new green printing materials project, reflecting a commitment to sustainability [32] Group 11 - Nova Star Cloud obtained a loan commitment letter from a bank for a share repurchase plan, indicating financial support for its capital management strategy [33] - Jimin Health established a joint venture for technology innovation, indicating a strategic move to enhance its technological capabilities [34] - Huili Pharmaceutical received a drug registration certificate for a medication used in treating digestive ulcers, expanding its product portfolio [35]

Core Viewpoint - China Resources Double Crane (600062.SH) announced that its wholly-owned subsidiary, Beijing Double Crane Run Chuang Technology Co., Ltd., has received the Drug Clinical Trial Approval Notice for DC6001 tablets from the National Medical Products Administration. The DC6001 tablets are intended for the treatment of Stargardt disease, a hereditary macular degeneration condition in adolescents [1]. Group 1 - The company has received regulatory approval for a new drug candidate [1] - The drug candidate DC6001 is aimed at treating a specific genetic condition affecting the youth [1] - This development may enhance the company's portfolio in the ophthalmology sector [1]

华润双鹤公告，公司全资子公司北京双鹤润创科技有限公司收到了国家药品监督管理局颁发的DC6001 片《药物临床试验批准通知书》。DC6001片拟用于青少年遗传性黄斑变性疾病(Stargardt病)。截至本公 告日，公司针对该药品累计研发投入为人民币1489.7万元(未经审计)。 ...